Global Anti-Cancer Drug Market- Market Overview:

The global Anti-Cancer drug market is expected to grow from USD 150.6 billion in 2022 to USD 266.5 billion by 2030, at a CAGR of 7.40% during the Projection period 2023-2030. The growth of the Anti-cancer drug market is mainly driven by owing to the increasing multiple cancer incidences, especially in developed economies.

Cancer is a dangerous disease in which the patient's body develops a tumor in a certain organ as a result of the growth of cancer cells. The body becomes weak and susceptible as a result of these malignant cells damaging the organ because of this the organ functions will alter. Anti-cancer drugs are hence the ones that are given to cancer patients to combat malignant cells. According to an article in Cancer Connect 2020, researchers from the Dana Farber Cancer Institute found that the six most frequent cancer types—breast, colorectal, lung, pancreatic, gastric, and esophageal cancers—had a 46% decline in diagnoses during the COVID-19 pandemic. Additionally, it was advised to delay elective surgeries, cancer screenings, and other health prevention services unless the risks outweighed the benefits and to prepare the hospital infrastructure for the care of COVID-19 patients by the Centers for Disease Control and Prevention (CDC) and many other medical professional organizations. Thus, the market for cancer therapies has been influenced by the COVID-19 pandemic.

Sample Request: - Global Anti-Cancer Drug Market

Market Dynamics:

Drivers:                          

• Increasing prevalence of Cancer

The rising incidence rate of different types of cancers, including skin cancer, liver cancer, and many more, is directly driving the demand for efficient medical care. The highest incidence rate of all cancers is lung cancer, therefore, an increase in prevalence would likely have a direct impact on the need for anti-cancer drugs.

Restraints:                                             

• High-Cost

The fear of failure and negative effects, along with the significant expenses involved in developing new drugs and research and development capabilities, will be one of the largest market barriers. Lack of awareness and the necessary infrastructure in underdeveloped economies, strict government rules regarding the approval of biosimilars, and unfavourable conditions would hinder the market's expansion rate. In addition, Unmet medical demands, a slow medication and inhibitor approval rate, and an increase in patent expiration cases will hinder the market growth.

Opportunities:

• Research and Development Activities

Increasing research and development activities is caused by increased strategic partnerships between public and private market actors. These capabilities in research and development for new drugs and medical technology will increase the demand for anti-cancer drug. Additionally, the introduction of novel cancer treatments, increased public and private activities to raise awareness, and the growing acceptance of cutting-edge therapies are the drivers that will accelerate market expansion. The market's growth rate will be positively impacted by additional variables such as the rise in demand for effective therapies, the availability of affordable medications, and the rising acceptance rate of early diagnostic techniques.

Challenges:

• Increase in Targeted Therapy Medication Advancements

These treatments are now preferred by patients and medical professionals because they are less likely to cause side effects than other options. This is a result of an increase in targeted therapy-based medication research and development over the past few years. As a result, there will be a direct impact on the growth of the market for pharmaceuticals used in supportive cancer care; as a result, the market's growth rate will be slowed down.

Segmentation Analysis:

The global Anti-Cancer drug market has been segmented based on indication, drug, route of administration, end-user, distribution channels, and region.

By Indication

The indication segment is breast cancer, lung cancer, prostate cancer, gynecologic cancer, gastrointestinal cancer, and others. The lung cancer segment led the largest share of the Anti-Cancer drug market with a market share of around 30% in 2022. Men are more likely than women to develop lung cancer. Nevertheless, men are more likely than women to acquire prostate disease in industrialized nations, particularly in North America and Europe. Breast is the most prevalent form observed in both developed and developing economies among females.

By Drug

The drug segment is cytotoxics, targeted therapy, hormonal therapy, and others. The targeted therapy segment led the largest share of the Anti-Cancer drug market with a market share of around 35% in 2022. In targeted therapy, which is used to treat cancer, the medications specifically target the genes or proteins that are present in the cancer cells. Apoptosis inducers, angiogenesis inhibitors, signal transduction inhibitors, hormone therapies, gene expression modulators, and many other treatments are examples of targeted therapeutics for cancer. Numerous new targets are being investigated in the rapidly expanding field of targeted therapy for cancer. For instance, some cancer cells have highly expressed human epidermal growth factor receptor 2 (HER-2) proteins on their surface. Trastuzumab (Herceptin), a medication licensed to treat some breast and stomach cancers that overexpress HER-2, is one of many targeted medicines that target this gene.

By End-User                                                                                     

The end-user segment is hospitals, home care, speciality clinics, and others. The hospital’s segment led the largest share of the Anti-Cancer drug market with a market share of around 33% in 2022. Hospitals with a safety-net mission, like the vital hospitals, have historically been committed to offering top-notch treatment to all populations and fulfill the responsibility of taking care of the patients.

Global Anti-Cancer Drug Market- Sales Analysis.

The sale of the Anti-Cancer drug market expanded at a CAGR of 6.70% from 2016 to 2022.

One major reason driving the expansion of the global anticancer drug market is the rise in cancer-related fatalities. Cancer is a group of diseases associated with abnormal cell growth that has the potential to hurt or spread to other body parts. Leukaemia, lymphomas, sarcomas, and carcinomas are among the more common types of tumors. Sarcomas develop in connective tissue, including muscle and bone. In oily tissues, delicate tissue sarcomas can begin. Additionally, the treatment of cancer in patients necessitates the use of numerous drugs, including hormone therapy, immunotherapy, focused therapy, and others.

Additionally, monoclonal antibody-based natural medicines (mAbs) have become popular to treat various cancer types, notably blood disorders (leukemia). The primary factors propelling the growth of the global oncology/malignancy pharmaceuticals market are the rise in prevalence of various illness conditions, expansion in the availability of advanced treatments (organic and drug-focused treatments), and a flood of the geriatric population in general. Additionally, increasing awareness of cancer and the availability of illness medications are necessary to promote market growth.

Thus, owing to the aforementioned factors, the global Anti-Cancer drug market is expected to grow at a CAGR of 7.40% during the Projection period from 2023 to 2030.

By Regional Analysis:

The regions analyzed for the Anti-Cancer drug market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region dominated the Anti-Cancer drug market and held a 38% share of the market revenue in 2022.

• The North America region witnessed a major share. Due to the increased use of cancer therapies and the rising incidence of cancer in the United States. The Globocan 2020 report estimates that there were approximately 612,390 cancer deaths and 2,281,658 new cancer cases in the United States in 2020. Breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) cancers were the most prevalent in the United States in 2020. The market in the region is anticipated to grow as a result of the high concentration of important players in North America, rising FDA approvals strategic alliances, and significant investment in R&D activities. In November 2020, for instance, Merck & Co. Velosbio Inc., a privately held clinical-stage biopharmaceutical business dedicated to creating first-in-class cancer treatments that target receptor tyrosine kinase-like orphan receptor 1, entered into a formal agreement to be acquired by Inc. (ROR1). Similarly, Johnson & Johnson earned US FDA Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372), which is used to treat people with metastatic non-small cell lung cancer, in March 2020. (NSCLC).
• Asia-Pacific is anticipated to experience significant growth during the Projection period. Oncology medicine sales are anticipated to develop steadily in Asia's emerging economies, particularly in China, India, Japan, and South Korea, as a result of rising cancer incidence, cigarette use, and population expansion. On account of the expansion of their healthcare infrastructure, China and India are anticipated to present favorable chances. Due to a lack of healthcare infrastructure, high medical costs, and poor consumer awareness, the business is predicted to grow at a slower rate in Japan.

Global Anti-Cancer Drug Market- Country Analysis:

• Germany

Germany's Anti-Cancer drug market size was valued at USD 0.11 billion in 2022 and is expected to reach USD 0.17 billion by 2030, at a CAGR of 5.8% from 2023 to 2030. Due to their lesser side effects, greater awareness of their availability, and supportive reimbursement rules for expensive targeted therapies, these regions have a high adoption rate for personalized and targeted therapies. Additionally, because they have fewer adverse effects, targeted medicines are widely used in these regions.

• China

China’s Anti-Cancer drug market size was valued at USD 0.16 billion in 2022 and is expected to reach USD 0.27 billion by 2030, at a CAGR of 6.9% from 2023 to 2030. Due to the good medical infrastructure and high levels of personal disposable resources in these locations, targeted therapy is a widely used form of treatment. Various elements are expected to be the main forces behind the market expansion in these regions.

• India

India's Anti-Cancer drug market size was valued at USD 0.15 billion in 2022 and is expected to reach USD 0.24 billion by 2030, at a CAGR of 6.3% from 2023 to 2030. The regional market is expanding as a result of growing knowledge of the advantages of early detection, increased disposable incomes, an increase in the prevalence of certain types of cancer, and anticipated pipeline medications.

Key Industry Players Analysis:                                                     

To increase their market position in the global anti-cancer drug business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.

• Pfizer Inc
• AstraZeneca
• ANI Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd
• Zydus Cadila
• Cipla Inc.
• Amneal Pharmaceuticals LLC
• Glenmark Pharmaceuticals Limited
• Fresenius Kabi AG
• Mayne Pharma Group Limited
• Mylan N.V.
• Novartis AG.
• Vintage Labs
• Reddy's Laboratories Ltd
• Jiangsu Hengrui Medicine Co., Ltd
• Novo Nordisk A/S
• Otsuka America Pharmaceutical, Inc.
• WOCKHARDT

Latest Development:

• In November 2020, the US Food & Drug Administration granted Merck Co. & Inc. approval to use Keytruda in conjunction with chemotherapy to treat triple-negative breast cancer.
• In June 2022, The Amgen Foundation will invest significantly more in Labxchange, a free online platform for science education.

Report Metrics

Report Attribute	Details
Study Period	2022-2030
Base year	2022
CAGR (%)	7.40%
Market Size	150.6 billion in 2022
Projection period	2023-2030
Projection unit	Value (USD)
Segments covered	By Indication, By Drug, By Route of Administration, By End-User, By Distribution Channel, and By Region.
Report Scope	Revenue Projection, competitive landscape, company ranking, growth factors, and trends
Companies covered	Pfizer Inc, AstraZeneca, ANI Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Cipla Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Mayne Pharma Group Limited, Mylan N.V., Novartis AG., Vintage Labs, Dr. Reddy's Laboratories Ltd, Jiangsu Hengrui Medicine Co., Ltd, Novo Nordisk A/S, Otsuka America Pharmaceutical, Inc., and WOCKHARDT.
By Indication	Breast Cancer Lung Cancer Prostate Cancer Gynecologic Cancer Gastrointestinal Cancer Others
By Drug	Cytotoxics Targeted Therapy Hormonal Therapy Others
By Route of Administration	Oral Parenteral Others
By End-User	Hospitals Homecare Specialty Clinics Others
By Distribution Channel	Hospital Pharmacy Online Pharmacy Retail Pharmacy
Regional scope	North America Europe Asia-Pacific South America Middle East and Africa

Scope of the Report

Global Anti-Cancer Drug Market By Indication:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Gynecologic Cancer
• Gastrointestinal Cancer
• Others

Global Anti-Cancer Drug Market By Drug:

• Cytotoxics
• Targeted Therapy
• Hormonal Therapy
• Others

Global Anti-Cancer Drug Market By Route of Administration:

• Oral
• Parenteral
• Others

Global Anti-Cancer Drug Market By End-User:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Anti-Cancer Drug Market By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Anti-Cancer Drug Market By Region:

• North America
  • USA
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
• South America
  • Brazil
  • Peru
• Middle East and Africa
  • UAE
  • South Africa
  • Saudi Arabia

Political Factors- In the world, there is a significant presence of the anti-cancer drug market. The producers of anti-cancer drugs have political solid ties across several countries. The manufacturers have put a lot of money into campaigning for favourable laws for their business. It requires the backing of political administrations because it provides healthcare services. All countries have a fairly stable political system, which makes it a good environment to run a business. The new government's plans should be taken into account by the anti-cancer drug market.

Economical Factors- The pandemic has caused substantial unemployment and decreased income levels for the populace. In this fiscal year, both the average family expenditure and the disposable income have significantly decreased. Government-sponsored economic stimulus measures may raise average household income and GDP, both of which are beneficial to businesses. The anti-cancer drug market should keep an eye on the rate of inflation, the GDP growth, and the vaccination programme that supports the country economy.

Social Factor- There is a high level of expertise in using healthcare services. Peoples are vigilant and closely monitor the healthcare industry. As they are more interested in healthcare services because of COVID. The producers of anti-cancer drugs should provide new services for the new age groups due to the changing demography. After the epidemic, the number of insurance plans bought by people in the 25–35 age range significantly increased. Manufacturers of anti-cancer drugs should be aware of the quick change. The epidemic also taught us to be proactive in health systems and avoid wasting money.

Technological Factors- The use of technology has significantly altered consumer behaviour. The procedure of receiving healthcare services is streamlined thanks to technology. Manufacturers of anti-cancer drugs should employ analytics to follow data and gather insightful information to create new goods and services. The business should adopt new technology to gather data and draw conclusions in order to provide services in an efficient manner. In order to protect the information, they can use cutting-edge technology like AI and blockchain.

Environmental Factors- The anti-cancer drug market didn't produce enough carbon dioxide to significantly contribute to climate change. But natural calamities will have an impact on the economy. People who used insurance and health care services would suffer economic losses as a result of this natural disaster. They might be unable to pay the premium, which would be bad for business. To increase its environmental contribution, the producers of anti-cancer drugs must invest heavily in these circumstances. The effects of natural calamities will also affect the company's activities. The makers must take precautions for risk management and should be aware of this danger.

Legal Factors- Manufacturers of anti-cancer drugs must abide by all applicable laws in their nation. To create new services and products, there are numerous laws and guidelines. When offering insurance services, they must adhere to governmental regulations. They apparently once caused a discrepancy in mental health care, which was quite expensive for the business. According to the US government, the business must also adhere to employment regulations. The business should also make sure that it complies with all state laws.

1. Introduction
   • 1. Objectives of the Study
   • 2. Market Definition
   • 3. Research Scope
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
   • 1. Porter’s Five Forces Analysis
   • 2. Value Chain Analysis
   • 3. Top Investment Pockets
     • 3.1. Market Attractiveness Analysis By Indication
     • 3.2. Market Attractiveness Analysis By Drug
     • 3.3. Market Attractiveness Analysis By Route of Administration
     • 3.4. Market Attractiveness Analysis By End-User
     • 3.5. Market Attractiveness Analysis By Distribution Channel
     • 3.6. Market Attractiveness Analysis By Region
   • 4. Industry Trends
5. Market Dynamics
   • 1. Market Evaluation
   • 2. Drivers
     • 2.1. Cancer Prevalence
   • 3. Restraints
     • 3.1. High-Cost
   • 4. Opportunities
     • 4.1. Research and Development Activities
   • 5. Challenges
     • 5.1. Increase in Targeted Therapy Medication Advancements

6. Global Anti-Cancer Drug Market Analysis and Projection, By Indication
   • 1. Segment Overview
   • 2. Breast Cancer
   • 3. Lung Cancer
   • 4. Prostate Cancer
   • 5. Gynecologic Cancer
   • 6. Gastrointestinal Cancer
   • 7. Others
7. Global Anti-Cancer Drug Market Analysis and Projection, By Drug
   • 1. Segment Overview
   • 2. Cytotoxics
   • 3. Targeted Therapy
   • 4. Hormonal Therapy
   • 5. Others
8. Global Anti-Cancer Drug Market Analysis and Projection, By Route of Administration
   • 1. Segment Overview
   • 2. Oral
   • 3. Parenteral
   • 4. Others
9. Global Anti-Cancer Drug Market Analysis and Projection, By End-User
   • 1. Segment Overview
   • 2. Hospitals
   • 3. Homecare
   • 4. Specialty Clinics
   • 5. Others
10. Global Anti-Cancer Drug Market Analysis and Projection, By Distribution Channel
    • Segment Overview
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
11. Global Anti-Cancer Drug Market Analysis and Projection, By Regional Analysis
    • Segment Overview
    • North America
      • 2.1. U.S.
      • 2.2. Canada
      • 2.3. Mexico
    • Europe
      • 3.1. Germany
      • 3.2. France
      • 3.3. U.K.
      • 3.4. Italy
      • 3.5. Spain
    • Asia-Pacific
      • 4.1. Japan
      • 4.2. China
      • 4.3. India
    • South America
      • 5.1. Brazil
    • Middle East and Africa
      • 6.1. UAE
      • 6.2. South Africa

12. Global Anti-Cancer Drug Market-Competitive Landscape
    • Overview
    • Market Share of Key Players in the Anti-Cancer Drug Market
      • 2.1. Global Company Market Share
      • 2.2. North America Company Market Share
      • 2.3. Europe Company Market Share
      • 2.4. APAC Company Market Share
    • Competitive Situations and Trends
      • 3.1. Product Launches and Developments
      • 3.2. Partnerships, Collaborations, and Agreements
      • 3.3. Mergers & Acquisitions
      • 3.4. Expansions

13. Company Profiles
    • Pfizer Inc
      • 1.1. Business Overview
      • 1.2. Company Snapshot
      • 1.3. Company Market Share Analysis
      • 1.4. Company Product Portfolio
      • 1.5. Recent Developments
      • 1.6. SWOT Analysis
    • AstraZeneca
      • 2.1. Business Overview
      • 2.2. Company Snapshot
      • 2.3. Company Market Share Analysis
      • 2.4. Company Product Portfolio
      • 2.5. Recent Developments
      • 2.6. SWOT Analysis
    • ANI Pharmaceuticals, Inc.
      • 3.1. Business Overview
      • 3.2. Company Snapshot
      • 3.3. Company Market Share Analysis
      • 3.4. Company Product Portfolio
      • 3.5. Recent Developments
      • 3.6. SWOT Analysis
    • Bristol-Myers Squibb Company
      • 4.1. Business Overview
      • 4.2. Company Snapshot
      • 4.3. Company Market Share Analysis
      • 4.4. Company Product Portfolio
      • 4.5. Recent Developments
      • 4.6. SWOT Analysis
    • Hikma Pharmaceuticals PLC
      • 5.1. Business Overview
      • 5.2. Company Snapshot
      • 5.3. Company Market Share Analysis
      • 5.4. Company Product Portfolio
      • 5.5. Recent Developments
      • 5.6. SWOT Analysis
    • Teva Pharmaceutical Industries Ltd
      • 6.1. Business Overview
      • 6.2. Company Snapshot
      • 6.3. Company Market Share Analysis
      • 6.4. Company Product Portfolio
      • 6.5. Recent Developments
      • 6.6. SWOT Analysis
    • Zydus Cadila
      • 7.1. Business Overview
      • 7.2. Company Snapshot
      • 7.3. Company Market Share Analysis
      • 7.4. Company Product Portfolio
      • 7.5. Recent Developments
      • 7.6. SWOT Analysis
    • Cipla Inc.
      • 8.1. Business Overview
      • 8.2. Company Snapshot
      • 8.3. Company Market Share Analysis
      • 8.4. Company Product Portfolio
      • 8.5. Recent Developments
      • 8.6. SWOT Analysis
    • Amneal Pharmaceuticals LLC
      • 9.1. Business Overview
      • 9.2. Company Snapshot
      • 9.3. Company Market Share Analysis
      • 9.4. Company Product Portfolio
      • 9.5. Recent Developments
      • 9.6. SWOT Analysis
    • Glenmark Pharmaceuticals Limited
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Fresenius Kabi AG
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Mayne Pharma Group Limited
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Mylan N.V.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Novartis AG.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Vintage Labs
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Reddy's Laboratories Ltd
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Jiangsu Hengrui Medicine Co., Ltd
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Novo Nordisk A/S
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Otsuka America Pharmaceutical, Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • WOCKHARDT
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis

List of Table

1. Global Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
2. Global Breast Cancer, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
3. Global Lung Cancer, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
4. Global Prostate Cancer, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
5. Global Gynecologic Cancer, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
6. Global Gastrointestinal Cancer, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
7. Global Others, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
8. Global Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
9. Global Cytotoxics, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
10. Global Targeted Therapy, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
11. Global Hormonal Therapy, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
12. Global Others, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
13. Global Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
14. Global Oral, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
15. Global Parenteral, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
16. Global Others, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
17. Global Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
18. Global Hospitals, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
19. Global Homecare, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
20. Global Specialty Clinics, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
21. Global Others, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
22. Global Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
23. Global Hospital Pharmacy, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
24. Global Online Pharmacy, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
25. Global Retail Pharmacy, Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
26. Global Anti-Cancer Drug Market, By Region, 2023–2030 (USD Billion)
27. North America Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
28. North America Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
29. North America Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
30. North America Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
31. North America Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
32. USA Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
33. USA Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
34. USA Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)  
35. USA Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)  
36. USA Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)  
37. Canada Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
38. Canada Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
39. Canada Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
40. Canada Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
41. Canada Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
42. Mexico Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
43. Mexico Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
44. Mexico Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
45. Mexico Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
46. Mexico Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
47. Europe Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
48. Europe Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
49. Europe Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
50. Europe Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
51. Europe Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
52. Germany Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
53. Germany Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
54. Germany Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
55. Germany Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
56. Germany Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
57. France Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
58. France Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
59. France Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
60. France Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
61. France Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
62. UK Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
63. UK Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
64. UK Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
65. UK Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
66. UK Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
67. Italy Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
68. Italy Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
69. Italy Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
70. Italy Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
71. Italy Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
72. Spain Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
73. Spain Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
74. Spain Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
75. Spain Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
76. Spain Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
77. Asia Pacific Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
78. Asia Pacific Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
79. Asia Pacific Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
80. Asia Pacific Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
81. Asia Pacific Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
82. Japan Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
83. Japan Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
84. Japan Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
85. Japan Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
86. Japan Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
87. China Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
88. China Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
89. China Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
90. China Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
91. China Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
92. India Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
93. India Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
94. India Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
95. India Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
96. India Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
97. South America Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
98. South America Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
99. South America Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
100. South America Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
101. South America Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
102. Brazil Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
103. Brazil Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
104. Brazil Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
105. Brazil Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
106. Brazil Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
107. Middle East and Africa Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
108. Middle East and Africa Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
109. Middle East and Africa Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
110. Middle East and Africa Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
111. Middle East and Africa Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
112. UAE Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
113. UAE Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
114. UAE Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
115. UAE Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
116. UAE Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)
117. South Africa Anti-Cancer Drug Market, By Indication, 2023–2030 (USD Billion)
118. South Africa Anti-Cancer Drug Market, By Drug, 2023–2030 (USD Billion)
119. South Africa Anti-Cancer Drug Market, By Route of Administration, 2023–2030 (USD Billion)
120. South Africa Anti-Cancer Drug Market, By End-User, 2023–2030 (USD Billion)
121. South Africa Anti-Cancer Drug Market, By Distribution Channel, 2023–2030 (USD Billion)

List of Figures 

1. Global Anti-Cancer Drug Market Segmentation
2. Anti-Cancer Drug Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Anti-Cancer Drug Market Attractiveness Analysis By Indication
9. Global Anti-Cancer Drug Market Attractiveness Analysis By Drug
10. Global Anti-Cancer Drug Market Attractiveness Analysis By Route of Administration
11. Global Anti-Cancer Drug Market Attractiveness Analysis By End-User
12. Global Anti-Cancer Drug Market Attractiveness Analysis By Distribution Channel
13. Global Anti-Cancer Drug Market Attractiveness Analysis By Region
14. Global Anti-Cancer Drug Market: Dynamics
15. Global Anti-Cancer Drug Market Share By Indication (2023 & 2030)
16. Global Anti-Cancer Drug Market Share By Drug (2023 & 2030)
17. Global Anti-Cancer Drug Market Share By Route of Administration (2023 & 2030)
18. Global Anti-Cancer Drug Market Share By End-User (2023 & 2030)
19. Global Anti-Cancer Drug Market Share By Distribution Channel (2023 & 2030)
20. Global Anti-Cancer Drug Market Share by Regions (2023 & 2030)
21. Global Anti-Cancer Drug Market Share by Company (2021)